Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies
Status:
Withdrawn
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
This is an open label phase I trial designed to evaluate the maximum tolerated dose,
dose-limiting toxicities, pharmacokinetics, and activity of the combination of alsertib
(MLN8237) and brentuximab vedotin in patients with relapsed/refractory CD30-positive
lymphomas and solid malignancies. Cohorts of 3-6 patients will receive escalating or
de-escalating doses of MLN8237 based on a 3 + 3 design.
Phase:
Phase 1
Details
Lead Sponsor:
Eric Bernicker, MD The Methodist Hospital System
Collaborators:
Millennium Pharmaceuticals, Inc. The Methodist Hospital Research Institute